Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
															Search

		Submit


Tuberculosis (TB)


Facebook
        Twitter
        LinkedIn
        Syndicate





2018 State and City TB Report										Related Pages
										Return to Program Evaluation
National TB Indicators are key process and outcome measures for TB control programs in the United States. These indicators are selected by CDC in cooperation with partners in state and local health departments. Data for calculating these indicators are derived from existing surveillance systems such as the National Tuberculosis Surveillance System (NTSS) and the Aggregate Reports for Program Evaluation (ARPE). CDC publishes TB indicator data to assist in:
Evaluating progress toward achievement of national objectives through monitoring of TB program performance
Assessment of needs for education and technical assistance
Identification of areas that need improvement.map iconIncidencemedical iconTreatment for LTBIbook iconCompletion of Therapychart iconRecent Transmissionbadge iconHIV Status**State and City Grouping**
The 2018 State & City Report provides key process and outcome measures for TB control programs for 50 states and 9 cities.The 2018 State & City TB Report provides key process and outcome measures for TB control programs for 50 states and 9 cities.
resize iconView Larger
CloseThe 2018 State & City Report provides key process and outcome measures for TB control programs for 50 states and 9 cities.The 2018 State & City TB Report provides key process and outcome measures for TB control programs for 50 states and 9 cities.
download iconDownload Image[PNG]
For the purposes of this report, states and cities were categorized into 3 groups based on the numbers of TB cases reported to NTSS. The cutoffs for the groups were determined by the numbers of cases that fell within the 33rd and 66th percentiles. City results for Baltimore, MD; Chicago, IL; District of Columbia; Houston, TX; Los Angeles, CA; New York City, NY; Philadelphia, PA; San Diego, CA; and San Francisco, CA are not included in the respective state results (e.g., percentage of known HIV results for Texas are exclusive of known HIV results for Houston).
**Indicator Year**
Data are presented for the relevant year for each indicator:
2018 for TB incidence and known HIV status
2017 for LTBI positive contacts of smear positive cases who started and completed preventive treatment
2016 for completion of treatment of newly diagnosed TB cases**Background & Data Sources**
Figure 11: Percentage of Contacts (to Sputum Acid-Fast Bacilli Smear-Positive TB Patients) Newly Diagnosed with Latent TB Infection Who Began Treatment, United States, 2017State and cities report new case data via the RCVT form – the national TB surveillance data reporting form. This report collects patient information, such as latent TB infection treatment completion.
resize iconView Larger
CloseFigure 11: Percentage of Contacts (to Sputum Acid-Fast Bacilli Smear-Positive TB Patients) Newly Diagnosed with Latent TB Infection Who Began Treatment, United States, 2017State and cities report new case data via the RCVT form – the national TB surveillance data reporting form. This report collects patient information, such as latent TB infection treatment completion.
download iconDownload Image[PNG]
The Centers for Disease Control and Prevention (CDC) provides funding for tuberculosis (TB) control activities in 50 U.S. states and 9 cities (Baltimore, MD; Chicago, IL; District of Columbia; Houston, TX; Los Angeles, CA; New York City, NY; Philadelphia, PA; San Diego, CA; and San Francisco, CA) through the *Tuberculosis Elimination and Laboratory Cooperative Agreement*(agreement number PS15-1501).  Information about each newly reported case of TB in the 50 states and 9 cities is submitted to CDC’s NTSS with a standard form, the Report of Verified Case of Tuberculosis (RVCT)pdf icon. The initial case report includes:
a patient’s demographic data, occupation, initial drug regimen
information on HIV status, substance use, housing status, and residence in correctional or long-term care facilitiesFollow-up reports collect drug susceptibility test results for *Mycobacterium tuberculosis* isolates and treatment status, among other items.
CDC also collects information from states and cities about their contact investigation activities: finding and examining persons who have had contact with TB cases and treating those found to have TB disease or latent TB infection (LTBI). Data for contact investigation are reported by each TB control jurisdiction annually through the ARPE.
Data in this report are based on the final 2018 dataset from the National TB Surveillance System (NTSS).
**For More Information:**
For more information about TB disease and TB prevention and control activities in the United States, visit the National TB Controllers Association websiteexternal icon.
For additional state-specific data not available in this report, you can contact your state TB control office.
For more information about the National TB Program Objectives and Performance Targets for 2025, please visit http://www.cdc.gov/tb/programs/evaluation/indicators/default.htm.

Additional ResourcesArchived State and City Reports
Fact Sheet: The National Tuberculosis Indicators Project (NTIP)
National TB Program Objectives and Performance Targets for 2025
Monitoring Tuberculosis Programs — National Tuberculosis Indicator Project, United States, 2002–2008
							
					
						Page last reviewed:  February 1, 2019					Content source: 	Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention homeTuberculosisBasic TB Factsplus iconHow TB SpreadsLatent TB Infection and TB DiseaseSigns & SymptomsTB Risk FactorsExposure to TBTB PreventionVaccinesTB & HIV CoinfectionTB and DiabetesTB TermsPersonal StoriesTesting & Diagnosisplus iconWho Should be TestedTesting for TB InfectionTesting in BCG-Vaccinated PersonsTB Screening and Testing of Health Care PersonnelTesting During PregnancyDiagnosing latent TB infection and TB diseaseTreatmentplus iconDeciding When to Treat Latent TB InfectionTreatment Regimens for Latent TB Infection (LTBI)Treatment for TB DiseaseAdverse EventsTB Treatment of Persons Living with HIVTB Treatment and PregnancyTB Treatment for ChildrenFrequently Asked QuestionsDrug-Resistant TBResearchplus iconTB Epidemiologic Studies Consortiumplus iconResearch ProjectsPublicationsTB Trials Consortiumplus iconStudy DescriptionsBackgroundBehavioral & Social Science ResearchHealth Care Settingsplus iconTB Infection Control in Health Care SettingsResources for TB Screening and Testing of Health Care Personnelplus iconFrequently Asked QuestionsTB in Specific Populationsplus iconHealth DisparitiesAsian PersonsBlack or African American PersonsHispanic or Latino PersonsChildrenPregnancyCorrectional FacilitiesPeople Experiencing HomelessnessInternational TravelersLaboratory Informationplus iconDrug Susceptibility TestingFalse-Positive Investigation ToolkitInterim Laboratory Biosafety Guidance for XDR  tuberculosis strainsModel Performance Evaluation Program (MPEP)Rapid Molecular Testing to Detect Drug-Resistant TB in the USplus iconExecutive SummaryIntroductionBackground on Tests for Molecular Detection of DRGeneral Considerations and Principles for a Molecular DR Testing ServicePossible Scenarios and Scope of Testing for a Molecular DR Testing ServiceResearch NeedsGeneral Recommendations of the Expert PanelCommunication Plan for the ReportRecommendationsReferencesPanel Members and CDC ParticipantsAppendix 1Appendix 2Appendix 3The Uses of Nucleic Acid Amplification Tests for the Diagnosis of TBplus iconGeneral ConsiderationsGeneral Recommendations of the Expert PanelRecommendations to ACET, CDC, DTBEData & Statisticsplus iconTB Incidence in the United StatesReported TB in the US, 2022 Surveillance Reportplus iconNational DataReporting Area DataRisk FactorsDemographicsTB Treatment and Case OutcomesDrug-Resistant TBMolecular SurveillanceTuberculosis in the United States, 2022 (Slide Set)Archived Surveillance Reports and Slide Sets2021 State and City ReportArchived State and City ReportsProfessional Resources & Toolsplus iconTools for Healthcare ProvidersResources for TB Programsplus iconStrengthening Civil Surgeons’ Capacity to Improve LTBI Surveillance and Outcomes Among Status AdjustersNotice of Funding Opportunity (NOFO)Program EvaluationTB Centers of ExcellenceTB Elimination AllianceTB Genotypingplus iconConventional TB GenotypingWhole Genome SequencingTB GIMSAnalytic ToolsLatent Tuberculosis Infection ResourcesPublications & Productsplus iconPatient and Public MaterialsFact SheetsGuidelinesplus iconControl & EliminationDrug-Resistant TBInfection Control & PreventionLaboratory & GenotypingTB & HIVTB in Specific PopulationsTesting & DiagnosisTreatmentVaccines & ImmunizationsArchived TB GuidelinesGuides & Toolkitsplus iconAggregate ReportsCDC TB Surveillance TrainingCore CurriculumEffective TB Interviewing for Contact InvestigationEthnographic GuidesFalse-Positive Investigation ToolkitForging Partnerships to Eliminate TuberculosisGuide to Application of GenotypingLTBI: A Guide for Primary Health Care ProvidersMantoux Tuberculin Skin Testing ProductsReport of Verified Case of Tuberculosis (RVCT)Self-Study ModulesTB Contact Investigation Interviewing Skills CourseTB eDOT ToolkitUnderstanding the TB Cohort Review ProcessNewslettersplus iconTB Notes, No. 4, 2023TB Notes, No. 3, 2023TB Notes. No. 2, 2023TB Notes. No. 1, 2023TB Notes, No. 4, 2022TB Notes, No. 3, 2022TB Notes, No. 2, 2022TB Notes, No. 1, 2022TB Notes, No. 4, 2021TB Notes, No. 3, 2021TB Notes, No. 2, 2021TB Notes, No. 1, 2021Pamphlets, Brochures, Bookletsplus iconQuestions and AnswersPatient Education SeriesTuberculosis - Get the FactsTuberculosis - The Connection between TB and HIV12-Dose Regimen for Latent TB Infection-Patient Education BrochurePostersplus iconMantoux Tuberculin Skin Test Wall ChartWorld TB DayThink TBStop TBTake on TBReports & Articlesplus iconDTBE Authored Journal ArticlesTuberculosis Laboratory Aggregate ReportsSlide Setsplus iconIntroduction to TuberculosisEpidemiology of Tuberculosis Among Non-U.S.​–Born Persons in the United States, 1993–2016Self-Study Modules on Tuberculosis, 1-5 Slide SetsThe Tuberculosis (TB) in Correctional Settingsplus iconFacilitator GuideIntroduction to TB GenotypingEpidemiology of Tuberculosis in Correctional Facilities, United States, 1993-2017Prevention and Control of Tuberculosis in Correctional and Detention FacilitiesGuidelines for Preventing the Transmission of M. TB in Health care SettingsInvestigation of Contacts of Persons with Infectious TBEpidemiology of Pediatric Tuberculosis in the United StatesTargeted Tuberculosis Testing and Treatment of Latent Tuberculosis InfectionElectronic Tools & ResourcesWeb-Based Courses & Webinarsplus iconTB 101 for Health Care WorkersContent SyndicationInfographicsplus iconSocial Media GraphicsCustomizable Take on TB Infographic with InstructionsEventsWorld TB Dayplus iconU.S. TB ChampionsHistoryFeaturesplus iconTB Risk FactorsTreating Latent TB Infection with Short-Course RegimensWorld Tuberculosis (TB) Day 2021World Tuberculosis (TB) Day 2020Linksplus iconState TB Control OfficesAbout Usplus iconMission Statement and Activitiesplus iconDTBE Strategic PlanNational TB Program ObjectivesOrganization ChartAdvisory Groupsplus iconFederal TB Task Force To receive email updates about this page, enter your email address: Email Address			What's this?				Submit


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue